Clinical Trial Detail

NCT ID NCT01015222
Title Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

Advanced Solid Tumor

Therapies

Methylnaltrexone Bromide

Dasatinib

Paclitaxel

Bevacizumab

Age Groups: adult

No variant requirements are available.